DOC,UTHR,TXMD Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: WELL VTR HCP OHI MPW HR NHI LTC SBRA GMRE

| Held by: VNQ VTI VOO VB VBR SPY RSP IVV XLRE SPYD

Index	S&P 500	P/E	-	EPS (ttm)	-0.06	Insider Own	0.33%	Shs Outstand	694.95M	Perf Week	-2.35%
Market Cap	11.80B	Forward P/E	54.79	EPS next Y	0.30	Insider Trans	0.37%	Shs Float	692.65M	Perf Month	-5.78%
Enterprise Value	21.74B	PEG	-	EPS next Q	0.07	Inst Own	96.66%	Short Float	3.11%	Perf Quarter	-8.93%
Income	-38.94M	P/S	4.21	EPS this Y	-96.75%	Inst Trans	0.71%	Short Ratio	2.65	Perf Half Y	-4.37%
Sales	2.80B	P/B	1.52	EPS next Y	2489.99%	ROA	-0.20%	Short Interest	21.52M	Perf YTD	-18.01%
Book/sh	10.93	P/C	73.87	EPS next 5Y	-4.43%	ROE	-0.48%	52W High	21.43 -22.46%	Perf Year	-22.48%
Cash/sh	0.22	P/FCF	10.25	EPS past 3/5Y	30.22% 52.84%	ROIC	-0.23%	52W Low	16.44 1.09%	Perf 3Y	-32.83%
Dividend Est.	1.22 (7.35%)	EV/EBITDA	13.64	Sales past 3/5Y	12.51% 16.84%	Gross Margin	21.83%	Volatility	2.26% 2.06%	Perf 5Y	-43.97%
Dividend TTM	1.12 (6.74%)	EV/Sales	7.76	EPS Y/Y TTM	-111.99%	Oper. Margin	18.65%	ATR (14)	0.38	Perf 10Y	-47.12%
Dividend Ex-Date	Dec 19, 2025	Quick Ratio	101.40	Sales Y/Y TTM	9.58%	Profit Margin	-1.39%	RSI (14)	33.85	Recom	1.90
Dividend Gr. 3/5Y	0.00% -4.11%	Current Ratio	101.40	EPS Q/Q	-237.83%	SMA20	-4.62%	Beta	1.10	Target Price	20.44
Payout	334.63%	Debt/Eq	1.24	Sales Q/Q	0.78%	SMA50	-7.24%	Rel Volume	0.75	Prev Close	16.68
Employees	387	LT Debt/Eq	1.24	Earnings	Oct 23 AMC	SMA200	-8.43%	Avg Volume	8.13M	Price	16.62
IPO	Jul 19, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-389.12% 0.50%	Trades		Volume	6,067,298	Change	-0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-25	Initiated	Cantor Fitzgerald	Neutral	$20
Sep-15-25	Upgrade	Raymond James	Mkt Perform → Outperform	$20
Aug-20-25	Downgrade	Deutsche Bank	Buy → Hold	$18
Jul-29-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$19
Jan-15-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$25
Oct-21-24	Upgrade	Deutsche Bank	Hold → Buy	$20 → $28
May-03-24	Upgrade	Wedbush	Neutral → Outperform
Apr-26-24	Upgrade	Exane BNP Paribas	Neutral → Outperform	$19 → $21
Apr-22-24	Resumed	Mizuho	Buy	$22
Apr-01-24	Upgrade	BofA Securities	Underperform → Buy	$18 → $25
Mar-25-24	Resumed	Wells Fargo	Equal Weight	$19
Mar-08-24	Resumed	RBC Capital Mkts	Outperform	$21
Jan-05-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-26-23	Initiated	JMP Securities	Mkt Outperform	$15.50
Apr-20-23	Initiated	Wells Fargo	Underweight	$14
Dec-14-22	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$17
Oct-28-22	Initiated	JP Morgan	Neutral	$17
Aug-05-22	Downgrade	Colliers Securities	Buy → Neutral	$19
Jun-03-22	Initiated	CapitalOne	Equal Weight	$20
May-19-22	Downgrade	BofA Securities	Neutral → Underperform	$18

Show Previous Ratings

Dec-11-25 09:40AM	Why Healthpeak (DOC) is a Top Value Stock for the Long-Term (Zacks)
Dec-10-25 11:47AM	This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500) (24/7 Wall St.)
Dec-08-25 06:00AM	Healthpeak Properties Publishes Updated Investor Presentation (Business Wire)
Dec-07-25 08:25PM	Got $2,000 to Invest in December? These Dividend Stocks Could Turn It into a Monthly Stream of Passive Income in 2026. (Motley Fool)
Dec-04-25 05:03PM	Wall Street Sees a 60% Upside to Healthpeak Properties (DOC) (Insider Monkey)
11:30AM	Loading…
Nov-27-25 11:30AM	W.P. Carey (WPC) Up 1.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 11:30AM	Why Is Alexandria Real Estate Equities (ARE) Down 16.4% Since Last Earnings Report? (Zacks)
Nov-25-25 11:48AM	3 Best Monthly Paying Dividend Stocks in the S&P 500 (24/7 Wall St.)
Nov-20-25 09:57AM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
Nov-11-25 06:36PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
Nov-05-25 01:15PM	Healthpeak Properties Stock: Is Wall Street Bullish or Bearish? (Barchart)
Nov-04-25 01:38PM	3 High-Yield Monthly Dividend Stocks That Pay You Like Clockwork (24/7 Wall St.)
Nov-03-25 07:03AM	3 Safe and Steady Stocks for Any Market (MarketBeat)
Oct-30-25 01:27PM	Ventas Q3 FFO and Revenues Beat Estimates, Same-Store Cash NOI Rises (Zacks)
01:07PM	Equinix Q3 AFFO Beats Estimates, Recurring Revenues Rise Y/Y (Zacks)
12:22PM	Loading…
Oct-28-25 12:22PM	Welltower's Q3 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks) -5.40%
Oct-24-25 05:02PM	Healthpeak Properties Inc (DOC) Q3 2025 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
01:34PM	Healthpeak Q3 FFO Beats Estimates, Same-Store NOI Rises Y/Y (Zacks)
Oct-23-25 06:00PM	Healthpeak (DOC) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:25PM	Healthpeak (DOC) Beats Q3 FFO and Revenue Estimates (Zacks)
04:21PM	Healthpeak: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Healthpeak Properties Provides Strategic Initiatives Update and Reports Third Quarter 2025 Results (Business Wire)
Oct-21-25 11:12AM	What's in the Cards for Healthpeak Properties This Earnings Season? (Zacks)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Healthpeak (DOC) Q3 Earnings (Zacks)
Oct-16-25 03:07PM	3 Ultra-High-Yield Dividend Stocks With 7.2% Average Yields to Buy in October (Motley Fool)
Oct-15-25 09:10AM	Prologis (PLD) Tops Q3 FFO Estimates (Zacks)
Oct-07-25 02:16AM	What to Expect From Healthpeak Properties Next Quarterly Earnings Report (Barchart)
Oct-06-25 04:15PM	Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Fourth Quarter of 2025 (Business Wire)
04:51AM	2 Top Dividend Stocks to Buy With Less Than $50 (Motley Fool)
Oct-05-25 08:17AM	Investing $50,000 Into These Top Real Estate Dividend Stocks Could Produce Nearly $250 of Passive Income Each Month (Motley Fool)
06:21AM	Loading…
Oct-03-25 06:21AM	Is AGNC Investment a Better Dividend Stock Than Healthpeak Properties? (Motley Fool)
Oct-01-25 01:00PM	Dividend Dependability: How Healthpeak Properties (DOC) Supports Long-Term Income Strategies (Insider Monkey)
Sep-28-25 06:33PM	2 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade (Motley Fool)
Sep-27-25 03:06AM	Investing $2,500 in This Basket of Dividend Stocks Should Give You Nearly $200 in Yearly Income (Motley Fool)
Sep-25-25 04:15PM	Healthpeak Properties Announces Third Quarter 2025 Earnings Release Date and Conference Call Details (Business Wire)
Sep-23-25 03:53AM	Is Healthpeak Properties Stock Underperforming the Nasdaq? (Barchart)
Sep-21-25 04:24AM	Street Calls of the Week (Investing.com)
Sep-15-25 09:40AM	Broadcom initiated, Beyond Meat downgraded: Wall Street's top analyst calls (The Fly)
08:56AM	Raymond James upgrades Healthpeak, downgrades Healthcare Realty to Underperform (Investing.com)
Sep-11-25 04:59AM	2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades (Motley Fool)
Sep-04-25 04:15PM	Healthpeak Properties Publishes Its 14th Annual Corporate Impact Report (Business Wire)
Sep-02-25 03:21AM	3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever (Motley Fool)
Aug-27-25 06:00AM	Healthpeak Strengthens Life Science Leadership with Addition of Denis Sullivan as Managing Director of Lab Investments & San Diego Market Lead and Promotion of Mike Dorris as Head of West Coast Development & Construction (Business Wire)
Aug-23-25 03:11AM	Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 5 Ultra-High-Yield Stocks. (Motley Fool)
Aug-20-25 08:13AM	2 Dirt-Cheap High-Dividend Stocks to Buy Right Now (Motley Fool)
Aug-19-25 02:04PM	Real Estate Is the S&P 500's Best Performer Today (Barrons.com)
Aug-16-25 10:28PM	Here's How You Can Earn $100 In Passive Income By Investing In Healthpeak Properties Stock (Benzinga)
Aug-15-25 10:00AM	Here's Why You Should Retain Welltower Stock in Your Portfolio Now (Zacks)
Aug-14-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-13-25 01:36AM	CEO Share Purchases Contrast Analyst Downgrades for Healthpeak (Insider Monkey)
Aug-07-25 10:21AM	Healthpeak Properties Stock: Analyst Estimates & Ratings (Barchart)
Aug-06-25 04:38AM	Zacks Investment Ideas feature highlights: MSCI, Charter Communications and Healthpeak Properties (Zacks)
Aug-05-25 05:27PM	Healthpeak Prices Offering of $500 Million of 4.750% Senior Unsecured Notes Due 2033 (Business Wire)
11:30AM	These 3 CEOs Just Bought the Dip (Zacks)
Jul-31-25 01:07PM	Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises (Zacks)
11:41AM	Equinix's Q2 AFFO Beat, Recurring Revenues Rise Y/Y, NFM Rises Q/Q (Zacks)
05:51AM	Want Another $500 in Annual Dividend Income? Invest $6,900 in These 3 High-Yield Stocks. (Motley Fool)
Jul-30-25 04:02PM	UPS Stock Joins 7% Dividend Yielders in S&P 500. Heres Who Else Is in That Club. (Barrons.com)
02:36PM	UPS Stock Joins 7% Yielders in S&P 500. Heres Who Else Is in the Club. (Barrons.com)
Jul-29-25 01:19PM	Welltower's Q2 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks)
Jul-26-25 10:36AM	Healthpeak Properties (DOC) Drops 6.7% on Steep Q2 Earnings Dive (Insider Monkey)
09:37AM	The Smartest Real Estate Dividend Stocks to Buy With $2,000 Right Now (Motley Fool)
03:08AM	Healthpeak Properties Inc (DOC) Q2 2025 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Jul-25-25 02:52PM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research) -6.73%
12:01PM	Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y (Zacks)
07:34AM	Healthpeak: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 06:00PM	Healthpeak (DOC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	Healthpeak (DOC) Q2 FFO Meet Estimates (Zacks)
04:15PM	Healthpeak Properties Reports Second Quarter 2025 Results (Business Wire)
Jul-22-25 02:11PM	What's in the Cards for Healthpeak Properties This Earnings Season? (Zacks)
Jul-21-25 09:15AM	Healthpeak (DOC) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Jul-19-25 04:27AM	2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now (Motley Fool)
Jul-14-25 08:02PM	Why I'm Reconsidering Ford's Role in My Portfolio: Is There a Better Investment for Income and Growth? (Motley Fool)
Jul-12-25 06:31PM	5 Top Dividend Stocks Yielding 5% or More to Buy Right Now for Passive Income (Motley Fool)
Jul-07-25 04:15PM	Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Third Quarter of 2025 (Business Wire)
07:45AM	What to Expect From Healthpeak Properties' Q2 2025 Earnings Report (Barchart)
Jul-04-25 09:50AM	Why Healthpeak (DOC) is a Top Momentum Stock for the Long-Term (Zacks)
Jun-26-25 04:15PM	Healthpeak Properties Announces Second Quarter 2025 Earnings Release Date and Conference Call Details (Business Wire)
Jun-24-25 09:13AM	Is Healthpeak Properties Stock Underperforming the S&P 500? (Barchart)
Jun-10-25 08:30AM	Healthpeak Properties, Inc. (NYSE: DOC) President and CEO Scott Brinker Interviewed by Advisor Access (GlobeNewswire)
Jun-07-25 06:30PM	3 Top High-Yield Dividend Stocks to Buy in June to Collect Passive Dividend Income Every Single Month (Motley Fool)
Jun-06-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-30-25 05:42AM	Supplement Your Paycheck by Investing in These High-Yield Monthly Dividend Stocks (Motley Fool)
May-29-25 11:49AM	Analyst Report: Healthpeak Properties, Inc. (Morningstar Research)
May-25-25 03:20PM	3 Top Monthly Dividend Stocks Yielding as Much as 7.2% to Buy for Passive Income (Motley Fool)
May-20-25 03:04AM	Better Dividend Stock: Healthpeak Properties vs. AGNC Investment (Motley Fool)
May-19-25 02:05PM	Is it Wise to Retain Healthpeak Properties Stock in Your Portfolio? (Zacks)
May-17-25 05:27AM	Want to Make $1,000 in Annual Passive Income? Invest $11,250 Into These Ultra-High-Yield Dividend Stocks. (Motley Fool)
May-14-25 05:27AM	Got $1,000 to Invest? This Healthy Monthly Dividend Stock Could Turn It Into Over $70 of Annual Passive Income. (Motley Fool)
May-13-25 09:40AM	Here's Why Healthpeak (DOC) is a Strong Value Stock (Zacks)
May-07-25 10:37AM	2 Undervalued Monthly Dividends With 5-7% Yields (Seeking Alpha)
08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
May-04-25 05:56PM	Healthpeak Properties, Inc. (DOC): Among the Best Falling Stocks to Buy According to Analysts (Insider Monkey)
May-03-25 08:05AM	5 Stocks I'm Buying As The Economy Dims And Dividends Shine (Seeking Alpha)
May-01-25 02:00PM	Rayonier's Q1 Earnings Miss Estimates, Revenues Decline Y/Y (Zacks)
10:25AM	Ventas Q1 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises (Zacks)
Apr-30-25 07:59PM	Is Healthpeak Properties, Inc. (DOC) the Best Buy-the-Dip Stock to Buy Now? (Insider Monkey)
Apr-29-25 01:11PM	American Tower Stock Gains on Q1 AFFO Beat, Revenues Rise Y/Y (Zacks)
12:23PM	Welltower's Q1 FFO & Revenues Beat Estimates, Same Store NOI Rises (Zacks)
09:35AM	Baron Real Estate Income Fund Q1 2025 Shareholder Letter (Seeking Alpha)

Healthpeak Properties, Inc. is a Standard & Poor's 500 company, which engages in acquiring, developing, owning, leasing, and managing healthcare real estate across the United States. It operates through the following segments: Lab, Outpatient Medical, Continuing Care Retirement Community (CCRC), and Other Non-Reportable. The Lab segment refers to lab properties, which contain laboratory and office space. The Outpatient Medical segment includes outpatient medical buildings and hospitals. The CCRC segment deals with retirement communities that include independent living, assisted living, memory care, and skilled nursing units. The Other Non-Reportable segment consists of an unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets and loans receivable. The company was founded in 1985 and is headquartered in Denver, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thomas John T	Director	Aug 06 '25	Buy	17.05	1,450	24,730	810,016	Aug 06 03:09 PM
Brinker Scott M	President and CEO	Aug 04 '25	Buy	16.83	1,490	25,077	211,906	Aug 04 11:16 AM
Brinker Scott M	President and CEO	Jul 31 '25	Buy	17.06	2,930	49,986	210,416	Jul 31 01:59 PM
Brinker Scott M	President and CEO	Jul 28 '25	Buy	17.40	2,873	49,990	207,486	Jul 29 12:02 PM
Scott Peter A	officer in 90 day cool down pe	Jul 01 '25	Proposed Sale	17.88	100,050	1,788,894		Jul 01 06:36 PM
Thompson Tommy G	Director	May 28 '25	Buy	17.27	5,777	99,769	144,290	May 28 01:15 PM
Thompson Tommy G	Director	May 09 '25	Buy	17.36	5,700	98,974	138,513	May 12 12:02 PM
Brinker Scott M	President and CEO	May 09 '25	Buy	17.39	2,750	47,822	204,613	May 12 12:01 PM
Lias-Booker Ava	Director	Apr 29 '25	Buy	17.83	5,000	89,150	35,561	Apr 29 05:06 PM
Thomas John T	Director	Apr 28 '25	Buy	17.84	4,200	74,928	813,566	Apr 28 05:56 PM
Sandstrom Katherine M	Director	Apr 28 '25	Buy	17.65	11,288	199,233	56,268	Apr 28 05:54 PM
Lewis Sara Grootwassink	Director	Apr 28 '25	Buy	17.66	6,000	105,938	9,000	Apr 28 05:52 PM
SHELLEY-KESSLER PAMELA	Director	Apr 28 '25	Buy	17.61	2,838	49,991	3,965	Apr 28 05:51 PM
Brinker Scott M	President and CEO	Apr 28 '25	Buy	17.68	11,337	200,438	201,863	Apr 28 05:49 PM

UTHR United Therapeutics Corp daily Stock Chart

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: IJH VTI VB VBR VXF XMHQ MDY IBB XBI IJK

Index	-	P/E	18.72	EPS (ttm)	26.39	Insider Own	3.54%	Shs Outstand	42.90M	Perf Week	0.96%
Market Cap	21.27B	Forward P/E	16.27	EPS next Y	30.36	Insider Trans	-37.19%	Shs Float	41.53M	Perf Month	7.03%
Enterprise Value	18.50B	PEG	1.77	EPS next Q	7.10	Inst Own	96.11%	Short Float	4.26%	Perf Quarter	22.54%
Income	1.27B	P/S	6.80	EPS this Y	11.61%	Inst Trans	-5.56%	Short Ratio	2.87	Perf Half Y	74.34%
Sales	3.13B	P/B	3.22	EPS next Y	10.42%	ROA	17.57%	Short Interest	1.77M	Perf YTD	40.00%
Book/sh	153.61	P/C	7.69	EPS next 5Y	9.20%	ROE	20.04%	52W High	492.62 0.28%	Perf Year	36.37%
Cash/sh	64.28	P/FCF	18.96	EPS past 3/5Y	34.80% -	ROIC	19.30%	52W Low	266.98 85.03%	Perf 3Y	78.28%
Dividend Est.	-	EV/EBITDA	11.57	Sales past 3/5Y	19.52% 14.71%	Gross Margin	88.59%	Volatility	1.98% 2.24%	Perf 5Y	280.05%
Dividend TTM	-	EV/Sales	5.91	EPS Y/Y TTM	17.16%	Oper. Margin	48.46%	ATR (14)	10.88	Perf 10Y	211.08%
Dividend Ex-Date	-	Quick Ratio	6.07	Sales Y/Y TTM	13.50%	Profit Margin	40.65%	RSI (14)	65.79	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	6.40	EPS Q/Q	12.12%	SMA20	2.81%	Beta	0.84	Target Price	526.09
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	6.76%	SMA50	8.07%	Rel Volume	0.80	Prev Close	488.51
Employees	1305	LT Debt/Eq	0.00	Earnings	Oct 29 BMO	SMA200	39.83%	Avg Volume	615.68K	Price	493.99
IPO	Jun 17, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.14% -1.64%	Trades		Volume	491,586	Change	1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Underweight	$414
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125

Show Previous Ratings

Dec-11-25 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Dec-09-25 12:26PM	This Gold Stock Hits A High, With Miner Poised For Huge Swing To Profit (Investor's Business Daily)
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
11:30AM	Loading…
Dec-05-25 11:30AM	Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:20AM	Can Merck's New Products Aid Growth as Keytruda LOE Test Looms? (Zacks)
Dec-03-25 07:19AM	Flurry of Bullish Inflows Sends United Therapeutics Higher (FX Empire)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-20-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Nov-19-25 10:52AM	Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study (Zacks)
Nov-12-25 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-09-25 11:02PM	3 Reasons Investors Love United Therapeutics (UTHR) (StockStory)
09:40AM	Loading…
Nov-05-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
12:35AM	The 5 Most Interesting Analyst Questions From United Therapeutics's Q3 Earnings Call (StockStory)
Nov-04-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease (Business Wire)
Oct-30-25 03:48PM	United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:40AM	MKKGY vs. UTHR: Which Stock Is the Better Value Option? (Zacks)
01:38AM	UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook (StockStory)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily) +9.63%
01:11PM	Why Is United Therapeutics (UTHR) Stock Soaring Today (StockStory)
11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:51AM	United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short (Investor's Business Daily)
07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks)
06:48AM	Loading…
06:48AM	United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
06:43AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results (Business Wire)
Oct-27-25 11:17PM	United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 10:05AM	Merck's Non-Oncology Drugs Q3 Performance: What to Expect (Zacks)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-22-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-16-25 03:51PM	Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case (Insider Monkey)
Oct-15-25 07:00AM	United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 (Business Wire)
Oct-13-25 07:00AM	United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting (Business Wire)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Sep-30-25 04:38PM	Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-19-25 11:53AM	Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE? (Zacks)
07:00AM	United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (Business Wire)
12:46AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
12:03AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
Sep-16-25 07:00AM	United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum (Business Wire)
Sep-12-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress (Business Wire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-10-25 02:46PM	United Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last Week (Investor's Business Daily)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
06:30AM	Lung Disease Breakthrough Boosts United Therapeutics and its Rivals (The Daily Upside)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +32.83%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
07:00AM	United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Aug-29-25 11:30AM	Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-13-25 12:05AM	5 Insightful Analyst Questions From United Therapeutics's Q2 Earnings Call (StockStory)
Aug-12-25 11:40PM	UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty (StockStory)
04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
Aug-11-25 04:15PM	3D Systems Reports Second Quarter 2025 Financial Results (GlobeNewswire)
11:32AM	Merck's Narrowed 2025 Sales View: What it Means After Q2 Results? (Zacks)
Aug-01-25 07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire) +7.13%
Jul-31-25 10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks) -5.25%
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics (Zacks)
07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
06:46AM	United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates (StockStory)
06:36AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results (Business Wire)
Jul-28-25 11:13PM	What To Expect From United Therapeutics's (UTHR) Q2 Earnings (StockStory)
10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
02:07AM	Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT (Insider Monkey)
Jul-25-25 10:42PM	United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial (Insider Monkey)
Jul-24-25 09:50AM	United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily)
Jul-23-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jul-21-25 06:32PM	United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag (Insider Monkey)
Jul-18-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jul-16-25 07:00AM	United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025 (Business Wire)
Jul-15-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jul-11-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jul-10-25 11:26PM	UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) (Insider Monkey)
Jul-09-25 12:33AM	1 Value Stock with Impressive Fundamentals and 2 to Turn Down (StockStory)
Jul-07-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-04-25 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-03-25 08:30AM	MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE (Zacks)
Jul-02-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jun-28-25 04:16AM	United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study (Insider Monkey)
Jun-26-25 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Jun-25-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
07:40AM	5 Must-Read Analyst Questions From United Therapeutics's Q1 Earnings Call (StockStory)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MALCOLM JAN	Director	Dec 11 '25	Sale	482.98	50	24,149	470	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Sale	484.67	11,000	5,331,316	36,781	Dec 12 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Sale	490.70	4,000	1,962,783	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Sale	483.97	4,000	1,935,879	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 12 '25	Proposed Sale	490.70	4,000	1,962,783		Dec 12 04:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 11 '25	Proposed Sale	483.97	4,000	1,935,879		Dec 11 04:10 PM
PAUL MAHON	Officer	Dec 11 '25	Proposed Sale	484.67	11,000	5,331,316		Dec 11 04:06 PM
Mesa Nilda	Director	Dec 09 '25	Sale	481.63	187	90,065	5,286	Dec 10 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Sale	480.05	4,000	1,920,191	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Sale	478.30	4,000	1,913,184	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 10 '25	Proposed Sale	480.05	4,000	1,920,190		Dec 10 03:52 PM
NILDA MESA	Director	Dec 09 '25	Proposed Sale	481.63	187	90,065		Dec 09 06:01 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Dec 09 04:54 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Sale	478.60	21,000	10,050,597	8,142	Dec 09 04:54 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Option Exercise	244.05	22,500	5,491,040	14,625	Dec 09 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Sale	478.58	22,500	10,768,000	0	Dec 09 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 09 '25	Proposed Sale	478.30	4,000	1,913,184		Dec 09 03:47 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 08 '25	Proposed Sale	484.23	4,000	1,936,936		Dec 08 06:25 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Sale	484.23	4,000	1,936,936	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Sale	483.28	4,000	1,933,120	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 03 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 04 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 04 '25	Sale	480.01	4,000	1,920,043	130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 03 '25	Sale	475.27	4,000	1,901,087	130	Dec 05 04:54 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 05 '25	Proposed Sale	483.28	4,000	1,933,120		Dec 05 04:18 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 04 '25	Proposed Sale	480.01	4,000	1,920,043		Dec 04 03:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 03 '25	Proposed Sale	475.27	4,000	1,901,088		Dec 03 03:21 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 01 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Dec 02 04:32 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 01 '25	Sale	479.99	21,000	10,079,696	8,142	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 01 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 02 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 01 '25	Sale	481.93	4,000	1,927,703	130	Dec 02 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 02 '25	Sale	481.29	4,000	1,925,143	130	Dec 02 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 01 '25	Option Exercise	127.65	22,500	2,872,226	14,625	Dec 02 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 01 '25	Sale	479.91	22,500	10,798,079	0	Dec 02 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 02 '25	Proposed Sale	481.29	4,000	1,925,143		Dec 02 03:58 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 01 '25	Proposed Sale	481.93	4,000	1,927,703		Dec 01 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 26 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 28 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 28 '25	Sale	487.64	4,000	1,950,550	130	Dec 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 26 '25	Sale	485.05	4,000	1,940,204	130	Dec 01 04:31 PM
JAMES EDGEMOND	Officer	Dec 01 '25	Proposed Sale	486.00	105,000	51,030,000		Dec 01 04:23 PM
Michael Benkowitz	Officer	Dec 01 '25	Proposed Sale	486.00	112,500	54,675,000		Dec 01 04:19 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 28 '25	Proposed Sale	487.64	4,000	1,950,550		Nov 28 04:08 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 24 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Nov 26 04:31 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 24 '25	Sale	473.64	21,000	9,946,544	8,142	Nov 26 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 24 '25	Option Exercise	137.07	22,500	3,084,146	12,000	Nov 26 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 24 '25	Sale	473.66	22,500	10,657,280	0	Nov 26 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 26 '25	Option Exercise	135.42	11,000	1,489,620	47,781	Nov 26 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 26 '25	Sale	486.06	11,000	5,346,701	36,781	Nov 26 04:30 PM
PAUL MAHON	Officer	Nov 26 '25	Proposed Sale	486.06	11,000	5,346,701		Nov 26 04:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 26 '25	Proposed Sale	485.05	4,000	1,940,204		Nov 26 03:45 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 24 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 25 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 25 '25	Sale	475.33	4,000	1,901,305	130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 24 '25	Sale	470.78	4,000	1,883,114	130	Nov 25 04:49 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 25 '25	Proposed Sale	475.33	4,000	1,901,305		Nov 25 03:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 24 '25	Proposed Sale	470.78	4,000	1,883,114		Nov 24 03:46 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 20 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 21 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 20 '25	Sale	478.38	4,000	1,913,524	130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 21 '25	Sale	474.64	4,000	1,898,558	130	Nov 21 05:26 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 21 '25	Proposed Sale	474.64	4,000	1,898,558		Nov 21 03:59 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 18 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 19 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 19 '25	Sale	474.58	4,000	1,898,336	130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 18 '25	Sale	472.76	4,000	1,891,037	130	Nov 20 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 20 '25	Proposed Sale	478.38	4,000	1,913,524		Nov 20 03:00 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 19 '25	Proposed Sale	474.58	4,000	1,898,336		Nov 19 02:40 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 17 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Nov 18 04:36 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 17 '25	Sale	470.43	22,500	10,584,756	0	Nov 18 04:36 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 17 '25	Option Exercise	146.03	21,000	3,066,630	18,806	Nov 18 04:35 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 17 '25	Sale	470.36	21,000	9,877,535	8,118	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 14 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 17 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 17 '25	Sale	467.55	4,000	1,870,192	130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 14 '25	Sale	462.94	4,000	1,851,774	130	Nov 18 04:35 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 18 '25	Proposed Sale	472.76	4,000	1,891,038		Nov 18 04:00 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 17 '25	Proposed Sale	467.55	4,000	1,870,192		Nov 17 04:10 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 14 '25	Proposed Sale	462.94	4,000	1,851,774		Nov 14 03:00 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 13 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 13 '25	Sale	728.96	4,000	2,915,859	130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 12 '25	Sale	460.00	4,000	1,839,996	130	Nov 13 06:32 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Nov 13 '25	Proposed Sale	463.35	4,000	1,853,409		Nov 13 04:37 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 13 '25	Option Exercise	135.42	11,000	1,489,620	47,781	Nov 13 04:33 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 13 '25	Sale	464.76	11,000	5,112,335	36,781	Nov 13 04:33 PM
PAUL MAHON	Officer	Nov 13 '25	Proposed Sale	464.76	11,000	5,112,335		Nov 13 04:04 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 10 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Nov 12 05:14 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 10 '25	Sale	452.07	22,500	10,171,683	0	Nov 12 05:14 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 10 '25	Option Exercise	146.03	21,000	3,066,630	29,118	Nov 12 05:13 PM
EDGEMOND JAMES	CFO AND TREASURER	Nov 10 '25	Sale	452.07	21,000	9,493,483	8,118	Nov 12 05:13 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Nov 12 04:31 PM

TXMD TherapeuticsMD Inc daily Stock Chart

Peers: VERU SNDX ARCT TGTX ONCY ATNM VRCA IBRX HRTG GNPX

| Held by: VTI VXF

Index	-	P/E	67.05	EPS (ttm)	0.03	Insider Own	1.55%	Shs Outstand	11.57M	Perf Week	0.57%
Market Cap	20.26M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	11.40M	Perf Month	4.17%
Enterprise Value	19.62M	PEG	-	EPS next Q	-	Inst Own	28.55%	Short Float	0.49%	Perf Quarter	62.04%
Income	0.30M	P/S	7.24	EPS this Y	-	Inst Trans	0.46%	Short Ratio	0.25	Perf Half Y	49.57%
Sales	2.80M	P/B	0.74	EPS next Y	-	ROA	0.19%	Short Interest	0.06M	Perf YTD	103.49%
Book/sh	2.37	P/C	2.85	EPS next 5Y	-	ROE	0.27%	52W High	2.44 -28.28%	Perf Year	38.89%
Cash/sh	0.62	P/FCF	9.79	EPS past 3/5Y	79.41% 64.95%	ROIC	0.92%	52W Low	0.70 150.00%	Perf 3Y	-70.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.87% -48.72%	Gross Margin	86.16%	Volatility	10.40% 15.04%	Perf 5Y	-97.22%
Dividend TTM	-	EV/Sales	7.01	EPS Y/Y TTM	109.08%	Oper. Margin	-93.71%	ATR (14)	0.19	Perf 10Y	-99.49%
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	75.19%	Profit Margin	10.80%	RSI (14)	55.86	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.46	EPS Q/Q	124.81%	SMA20	3.77%	Beta	0.42	Target Price	5.00
Payout	-	Debt/Eq	0.24	Sales Q/Q	43.33%	SMA50	24.45%	Rel Volume	0.18	Prev Close	1.84
Employees	1	LT Debt/Eq	0.20	Earnings	Nov 12 AMC	SMA200	46.99%	Avg Volume	224.21K	Price	1.75
IPO	Jan 03, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	39,998	Change	-4.89%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy	$7
Apr-30-19	Resumed	Noble Capital Markets	Outperform	$13
Jun-15-18	Initiated	JP Morgan	Overweight	$11
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight	$6
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy	$18
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy	$10
Dec-08-15	Reiterated	Stifel	Buy	$10 → $14
Dec-08-15	Reiterated	Jefferies	Buy	$15 → $18
Sep-21-15	Reiterated	Jefferies	Buy	$7 → $15
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform	$34
Apr-17-14	Reiterated	Noble Financial	Buy	$9 → $13
Jan-28-14	Reiterated	Noble Financial	Buy	$7.25 → $9

Show Previous Ratings

Nov-12-25 06:04PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2025 Financial Results (Business Wire)
Aug-12-25 04:47PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2025 Financial Results (Business Wire)
May-13-25 05:02PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	TherapeuticsMD Announces First Quarter 2025 Financial Results (Business Wire)
Mar-27-25 04:05PM	TherapeuticsMD Announces Full Year 2024 Financial Results (Business Wire) -6.48%
Nov-12-24 04:32PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2024 Financial Results (Business Wire)
Aug-12-24 05:26PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2024 Financial Results (Business Wire)
Jun-28-24 11:52AM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023 (InvestorPlace) -7.47%
May-10-24 08:53PM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024 (InvestorPlace)
04:43PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2024 Financial Results (Business Wire)
04:00PM	Loading…
Mar-29-24 04:00PM	TherapeuticsMD Announces Full Year 2023 Financial Results (Business Wire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey) +6.95%
Jan-30-24 11:20PM	12 Best Prenatal Vitamins For Pregnant Women (Insider Monkey)
Nov-15-23 05:08AM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance) +17.41%
Nov-14-23 04:05PM	TherapeuticsMD Announces Third Quarter 2023 Financial Results (Business Wire)
Aug-14-23 07:52AM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	TherapeuticsMD Announces Second Quarter 2023 Financial Results (Business Wire)
May-15-23 05:56PM	TherapeuticsMD: Q1 Earnings Snapshot (AP Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2023 Financial Results (Business Wire)
Apr-14-23 12:00PM	All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy (Zacks)
Apr-07-23 04:01PM	TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition (Business Wire)
Jan-03-23 06:50AM	TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma (Business Wire) +11.81%
Dec-08-22 10:42AM	Boca pharma company will cut 212 employees after failed buyout (American City Business Journals)
Dec-04-22 06:00PM	TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma (Business Wire)
Nov-14-22 07:55PM	TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.45% -8.20%
04:05PM	Loading…
04:05PM	TherapeuticsMD Announces Third Quarter 2022 Financial Results (Business Wire)
Oct-31-22 06:50AM	TherapeuticsMD Announces Additional $7 Million Private Placement (Business Wire) +6.21%
Oct-03-22 01:45PM	TherapeuticsMD receives $7M investment after merger plans unravel (American City Business Journals) -7.53%
06:50AM	TherapeuticsMD Announces $7 Million Private Placement (Business Wire)
Sep-12-22 06:50AM	TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers (Business Wire) +5.55%
Aug-15-22 01:00PM	TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript (Motley Fool)
08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Second Quarter 2022 Financial Results (Business Wire)
Aug-08-22 06:50AM	TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022 (Business Wire)
Aug-01-22 01:00PM	Pharma firm receives $15M investment after canceled merger (American City Business Journals) +36.60%
06:50AM	TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital (Business Wire)
Jul-15-22 01:34PM	HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path' (Benzinga) +12.50%
Jul-13-22 09:48AM	Why TherapeuticsMD Shares Are Sinking Today? (Benzinga) -35.55%
08:25AM	TherapeuticsMD's stock falls 41% after tender offer expires (MarketWatch)
06:50AM	TherapeuticsMD Announces Expiration of Tender Offer (Business Wire)
Jul-06-22 06:09AM	EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer (PR Newswire)
Jun-06-22 04:05PM	EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD (PR Newswire)
May-31-22 06:00AM	TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD (Business Wire) +364.02%
May-20-22 10:52AM	Why TherapeuticsMD Shares Are Trading Higher Today (Benzinga) +36.56%
09:43AM	TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA® (Business Wire)
May-16-22 08:00PM	TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript (Motley Fool) -14.01%
05:45PM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	TherapeuticsMD Announces First Quarter 2022 Financial Results (Business Wire)
May-12-22 05:25PM	Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.87%
May-10-22 04:05PM	TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 (Business Wire) -24.78%
Apr-14-22 04:15PM	TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million (Business Wire)
Mar-10-22 01:30PM	TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript (Motley Fool) -27.50%
08:05AM	TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Fourth Quarter 2021 Financial Results (Business Wire)
Mar-07-22 12:57PM	TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal (Benzinga) +43.05%
07:40AM	TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx (Business Wire)
Mar-01-22 04:30PM	TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022 (Business Wire) -5.69%
Feb-28-22 05:35PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +8.28%
Feb-24-22 09:05AM	Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Jan-25-22 08:52AM	TherapeuticsMD, Inc. (NASDAQ:TXMD): Is Breakeven Near? (Simply Wall St.)
Jan-06-22 07:29AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jan-04-22 06:20AM	FDA Approves TherapeuticsMD's Low Dose Bijuva (Benzinga) +11.18%
Dec-28-21 09:53AM	Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options (Zacks)
Dec-13-21 06:08AM	TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits (Benzinga) -11.51%
Dec-10-21 04:30PM	U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA® (Business Wire)
Dec-08-21 06:50AM	TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) Allowing for a May 25, 2032 Generic Entry Date (Business Wire)
Nov-24-21 07:54AM	TherapeuticsMD (NASDAQ:TXMD) investors are sitting on a loss of 90% if they invested five years ago (Simply Wall St.)
Nov-22-21 10:40AM	Therapeuticsmd Insider Trades $580K In Company Stock (Benzinga)
Nov-12-21 03:00AM	TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-11-21 06:50AM	TherapeuticsMD Announces Third Quarter 2021 Financial Results (Business Wire) -7.82%
06:45AM	TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh ODowd, as Chief Executive Officer (Business Wire)
Nov-04-21 03:01PM	TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-27-21 05:00PM	TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021 (Business Wire)
Oct-15-21 05:33PM	TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer (Business Wire)
Oct-05-21 01:28PM	What Type Of Shareholders Own The Most Number of TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares? (Simply Wall St.)
Oct-04-21 09:20AM	Where Do Hedge Funds Stand On TherapeuticsMD Inc (TXMD)? (Insider Monkey)
Sep-02-21 06:50AM	Therapeutics MD Is Urging Women to Take Pause During Menopause Awareness Month (Business Wire) +7.71%
Aug-23-21 06:50AM	TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector (Business Wire) +7.12%
Aug-19-21 08:01AM	5 Penny Stocks Insiders Are Buying (Benzinga) +5.53%
Aug-09-21 04:30PM	TherapeuticsMD Announces Appointment of Hugh ODowd as President (Business Wire)
Aug-04-21 08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.66%
06:50AM	TherapeuticsMD Announces Second Quarter 2021 Financial Results (Business Wire)
Jul-28-21 03:03PM	Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-26-21 06:50AM	TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021 (Business Wire)
Jul-06-21 11:49AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman (Insider Monkey)
Jun-29-21 08:58AM	Breakeven On The Horizon For TherapeuticsMD, Inc. (NASDAQ:TXMD) (Simply Wall St.)
May-25-21 06:50AM	TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA (Business Wire)
May-24-21 07:00AM	The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award (Business Wire)
May-07-21 01:31AM	TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript (Motley Fool)
May-06-21 10:56AM	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume (Benzinga) -13.28%
08:20AM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TherapeuticsMD Announces First Quarter 2021 Financial Results (Business Wire)
06:45AM	TherapeuticsMD, Inc. to Host Earnings Call (ACCESSWIRE)
May-03-21 07:00AM	TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting (Business Wire)
Apr-29-21 10:34AM	TherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares (Simply Wall St.)

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Tommy G	Director	Apr 14 '25	Buy	1.00	325	326	14,779	Apr 15 07:59 AM
Walker Marlan D	Chief Executive Officer	Apr 14 '25	Buy	1.00	490	489	73,639	Apr 15 07:59 AM
Walker Marlan D	Chief Executive Officer	Apr 10 '25	Buy	0.86	1,167	1,000	73,149	Apr 10 04:29 PM
Walker Marlan D	Chief Executive Officer	Apr 09 '25	Buy	0.87	1,136	994	71,982	Apr 10 04:29 PM
Collins Cooper C.	Director	Feb 18 '25	Option Exercise	0.00	8,500	0	60,516	Feb 20 09:08 PM
Naughton Gail K	Director	Feb 18 '25	Option Exercise	0.00	8,500	0	8,500	Feb 20 09:07 PM
Thompson Tommy G	Director	Feb 18 '25	Option Exercise	0.00	8,500	0	14,454	Feb 20 09:07 PM
Walker Marlan D	Chief Executive Officer	Feb 18 '25	Option Exercise	0.00	8,281	0	70,846	Feb 20 09:07 PM

DOC

Healthpeak Properties Inc

UTHR

United Therapeutics Corp

TXMD

TherapeuticsMD Inc

Upgrade your FINVIZ experience